NCT05842785View on ClinicalTrials.gov

TSN222 in Subjects With Advanced Solid Tumors or Lymphomas

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

July 26, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions
Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma
Interventions
DRUG

Phase I dose escalation

The eligible subjects will receive TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.

DRUG

Phase II-HNSCC

The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.

DRUG

Phase II-Advanced melanoma

The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.

DRUG

Phase II-solid tumors or lymphomas

The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.

Trial Locations (1)

200063

RECRUITING

Fudan Cancer Hospital, Shanghai

All Listed Sponsors
lead

Tyligand Bioscience (Shanghai) Limited

INDUSTRY